Evidence map›Paper›PMID 37978501›Full record

ArticleRespiratory research2023

Spatially distinct molecular patterns of gene expression in idiopathic pulmonary fibrosis.

Rachel Z Blumhagen, Jonathan S Kurche, Carlyne D Cool, Avram D Walts, David Heinz, Tasha E Fingerlin, Ivana V Yang, David A Schwartz

Open access · goldAbstract read
In one paragraph

Article in Respiratory research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Altered cholesterol immunometabolism activates the macrophage NLRP3-inflammasome in lung fibrosis.American journal of respiratory cell and molecular biology · 2026
    Article
  4. Article
  5. Article
  6. [Spatial omics in pulmonary fibrosis: advancing mechanistic insights and therapeutic strategies].Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2026
    Review
  7. Mechanobiology and Resolution of Lung Fibrosis.Annual review of physiology · 2026
    Review
  8. Article
  9. Article
  10. Review
  11. Mechanosensing Pathways in the Progression of Pulmonary Fibrosis.Current opinion in biomedical engineering · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Role of Inflammation and Fibrosis in Interstitial Lung Disease Treatment Decisions.American journal of respiratory and critical care medicine · 2024
    Article
  17. Article
  18. Genetics of chronic respiratory disease.Nature reviews. Genetics · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Rachel Z Blumhagen *Center for Genes, Environment and Health, National Jewish Health, 1400 Jackson St, Office M222D, Denver, CO, 80206, USA. blumhagenr@njhealth.org.
Jonathan S Kurche *Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO, 80045, USA.
Carlyne D Cool *Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO, 80045, USA.
Avram D WaltsDepartment of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO, 80045, USA.
David HeinzPathology Laboratory, National Jewish Health, 1400 Jackson St., Denver, CO, 80206, USA.
Tasha E FingerlinCenter for Genes, Environment and Health, National Jewish Health, 1400 Jackson St, Office M222D, Denver, CO, 80206, USA.
Ivana V Yang *Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO, 80045, USA.
David A Schwartz *Department of Medicine, University of Colorado Anschutz Medical Campus, 13001 E. 17th Place, Aurora, CO, 80045, USA.
University of Colorado Anschutz Medical Campus · USNational Jewish Health · USUniversity of Colorado Denver · US

Funding

Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLACKWELL, TIMOTHY S. · 2010 to 2020
$21.6M
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)R01HL097163 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI FINGERLIN, TASHA E., SCHWARTZ, DAVID ALBERT · 2009 to 2018
$16.4M
Targeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH3HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2016 to 2018
$4.8M
Molecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5M
MUC5B, a novel therapeutic target for Idiopathic Pulmonary Fibrosis (IPF)UH2HL123442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2014 to 2015
$3.0M
Genes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0M
Development and Validation of a Prognostic Transcriptomic Signature for Chronic Hypersensitivity PneumonitisR01HL148437 · NHLBI · NATIONAL JEWISH HEALTH · PI FERNANDEZ, EVANS, VESTAL, BRIAN E · 2020 to 2023
$2.5M
Preclinical Pulmonary Fibrosis, an opportune rare disease cohortUG3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2020 to 2021
$1.7M
BLRD VA I01 BX005295NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01-HL092870NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01 HL097163NHLBI NIH HHS R01-HL097163NHLBI NIH HHS R01 HL148437NHLBI NIH HHS R01-HL148437NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL158668NHLBI NIH HHS R01-HL158668NHLBI NIH HHS UG3 HL151865NHLBI NIH HHS UG3-HL151865NHLBI NIH HHS UH2 HL123442NHLBI NIH HHS UH3 HL123442NHLBI NIH HHS UH3- HL123442
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a heterogeneous disease that is pathologically characterized by areas of normal-appearing lung parenchyma, active fibrosis (transition zones including fibroblastic foci) and dense fibrosis. Defining transcriptional differences between these pathologically heterogeneous regions of the IPF lung is critical to understanding the distribution and extent of fibrotic lung disease and identifying potential therapeutic targets. Application of a spatial transcriptomics platform would provide more detailed spatial resolution of transcriptional signals compared to previous single cell or bulk RNA-Seq studies.

methodsWe performed spatial transcriptomics using GeoMx Nanostring Digital Spatial Profiling on formalin-fixed paraffin-embedded (FFPE) tissue from 32 IPF and 12 control subjects and identified 231 regions of interest (ROIs). We compared normal-appearing lung parenchyma and airways between IPF and controls with histologically normal lung tissue, as well as histologically distinct regions within IPF (normal-appearing lung parenchyma, transition zones containing fibroblastic foci, areas of dense fibrosis, and honeycomb epithelium metaplasia).

resultsWe identified 254 differentially expressed genes (DEGs) between IPF and controls in histologically normal-appearing regions of lung parenchyma; pathway analysis identified disease processes such as EIF2 signaling (important for cap-dependent mRNA translation), epithelial adherens junction signaling, HIF1α signaling, and integrin signaling. Within IPF, we identified 173 DEGs between transition and normal-appearing lung parenchyma and 198 DEGs between dense fibrosis and normal lung parenchyma; pathways dysregulated in both transition and dense fibrotic areas include EIF2 signaling pathway activation (upstream of endoplasmic reticulum (ER) stress proteins ATF4 and CHOP) and wound healing signaling pathway deactivation. Through cell deconvolution of transcriptome data and immunofluorescence staining, we confirmed loss of alveolar parenchymal signals (AGER, SFTPB, SFTPC), gain of secretory cell markers (SCGB3A2, MUC5B) as well as dysregulation of the upstream regulator ATF4, in histologically normal-appearing tissue in IPF.

conclusionsOur findings demonstrate that histologically normal-appearing regions from the IPF lung are transcriptionally distinct when compared to similar lung tissue from controls with histologically normal lung tissue, and that transition zones and areas of dense fibrosis within the IPF lung demonstrate activation of ER stress and deactivation of wound healing pathways.

Indexed as

Eukaryotic Initiation Factor-2Idiopathic Pulmonary FibrosisFibrosisHumansLungTranscriptomeEukaryotic Initiation Factor-2

Identifiers

PMID37978501
PMCPMC10655274
OpenAlexW4388774583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.